Delcath Systems (NASDAQ:DCTH - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $22.00 price objective on the stock. HC Wainwright's price target would suggest a potential upside of 120.88% from the company's current price.
DCTH has been the topic of a number of other research reports. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $21.00 price target on shares of Delcath Systems in a report on Friday, October 18th. Stephens reiterated a "buy" rating on shares of Delcath Systems in a research note on Friday, October 18th. Finally, StockNews.com upgraded shares of Delcath Systems from a "sell" rating to a "hold" rating in a research note on Friday, October 25th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $21.50.
Get Our Latest Stock Analysis on Delcath Systems
Delcath Systems Trading Down 9.9 %
Shares of NASDAQ:DCTH traded down $1.10 during mid-day trading on Monday, reaching $9.96. The company had a trading volume of 763,412 shares, compared to its average volume of 270,802. The firm has a market cap of $276.79 million, a price-to-earnings ratio of -7.39 and a beta of 0.75. The company's 50-day moving average price is $9.78 and its 200-day moving average price is $8.36. Delcath Systems has a one year low of $2.25 and a one year high of $12.88.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of DCTH. Riverwater Partners LLC purchased a new position in shares of Delcath Systems during the 3rd quarter valued at $161,000. Levin Capital Strategies L.P. grew its position in shares of Delcath Systems by 12.2% during the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company's stock valued at $262,000 after purchasing an additional 5,969 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Delcath Systems during the 2nd quarter valued at $370,000. Renaissance Technologies LLC purchased a new position in shares of Delcath Systems during the 2nd quarter valued at $694,000. Finally, Marshall Wace LLP grew its position in shares of Delcath Systems by 7.0% during the 2nd quarter. Marshall Wace LLP now owns 92,731 shares of the company's stock valued at $776,000 after purchasing an additional 6,066 shares in the last quarter. 61.12% of the stock is currently owned by hedge funds and other institutional investors.
Delcath Systems Company Profile
(
Get Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Further Reading
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
